Please assess the completion status of the following clinical trial:

Trial Title: PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New diagnosis of symptomatic Crohn's disease or an established diagnosis of Crohn's disease with a suspected flare.~* Appropriate clinical candidate for infliximab induction therapy, as determined by the patient's gastroenterologist~Exclusion Criteria:~* Anti-TNF medications in the previous 6 months~* Pregnancy or plan to become pregnant~* Severe claustrophobia, sufficient to preclude PET/CT scanning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab responders (Type: None): Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
- Infliximab non-responders (Type: None): Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).